	US 11,999,779 B2
	Anti-complement factor C1q Fab fragments and uses thereof
Ted Yednock, Forest Knolls, CA (US); Sethu Sankaranarayanan, Fremont, CA (US); Michael Leviten, Emerald Hills, CA (US); and Arnon Rosenthal, Woodside, CA (US)
Assigned to Annexon, Inc., Brisbane, CA (US)
Filed by Annexon, Inc., South San Francisco, CA (US)
Filed on Jun. 25, 2020, as Appl. No. 16/911,954.
Application 16/911,954 is a division of application No. 15/360,549, filed on Nov. 23, 2016, granted, now 10,723,788.
Claims priority of provisional application 62/259,227, filed on Nov. 24, 2015.
Prior Publication US 2020/0317765 A1, Oct. 8, 2020
Int. Cl. C07K 16/18 (2006.01); G01N 33/564 (2006.01); G01N 33/68 (2006.01)

CPC C07K 16/18 (2013.01) [G01N 33/564 (2013.01); G01N 33/6857 (2013.01); G01N 33/6893 (2013.01); C07K 2317/24 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/4716 (2013.01); G01N 2800/50 (2013.01); G01N 2800/7095 (2013.01)]

19 Claims

1. A method of inhibiting synapse loss comprising administering to a patient suffering from adverse synapse loss an antibody Fab fragment that binds to C1q, wherein the antibody Fab fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises SEQ ID NO:1 and the light chain comprises SEQ ID NO:2.